Anavex Life Sciences Corp (AVXL)

[boi568]

The controlled market reaction today to a totally successful, critically important Phase 2 trial tells me that the adverse reaction to all the good news in the incomplete PDD Phase 2 was not really about a problem with the CDR-COA subscales -- especially when the more commercially significant Episodic Memory results were ignored. For whatever reasons, and through whatever means, AVXL shares are under serious selling pressure that does not reflect recent material events. Today the market cap rose about $48M on news worth perhaps 10 times that.

Let's see if things straighten out over the next few days; I expect some favorable analyst reviews.